“Bimekizumab Efficacy and Safety through Three Years in Patients With Moderate to Severe Plaque Psoriasis: Long-Term Results from the BE SURE Randomized Controlled Trial and the BE BRIGHT Open-Label Extension”. SKIN The Journal of Cutaneous Medicine, vol. 6, no. 6, Nov. 2022, p. s68, https://doi.org/10.25251/skin.6.supp.68.